Answers are grounded in this paper and cite their sources.
Case report analyzes clinical features and treatment outcomes in a child with isovaleric acidemia, indicating early diagnosis is crucial.
To improve understanding of isovaleric acidemia (IVA) by analyzing the clinical features, genetic basis, and treatment outcomes of a child with chronic intermittent IVA. A 4‐month‐old infant presenting with lethargy, pallor, and growth retardation was diagnosed with IVA using tandem mass spectrometry (MS/MS), urinary organic acid analysis, and genetic testing. MS/MS and urine gas chromatography–mass spectrometry revealed elevated isovalerylcarnitine and isovalerylglycine. Whole‐exome sequencing identified a novel homozygous IVD gene variant (c.899_905delinsCCCACAG) in the proband, with both parents confirmed as carriers. The patient was treated with a leucine‐restricted diet, glycine, L‐carnitine, and arginine. Follow‐up showed reduced metabolite levels and improved neurodevelopment. IVA is an autosomal recessive disorder caused by isovaleryl‐CoA dehydrogenase deficiency, leading to toxic metabolite accumulation. Clinical symptoms are nonspecific, often resulting in misdiagnosis. Early use of MS/MS and genetic testing enables timely diagnosis and targeted treatment, improving outcomes.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: